ArticleJournal of medical case reports2026
Autoimmune encephalitis associated with anti-recoverin antibodies.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutoimmune encephalitis (AE) is a spectrum of autoimmune disorders manifesting by epilepsy, loss of consciousness, and neuropsychiatric symptoms. Anti-recoverin antibodies are intracellular antibodies and a well-known marker of paraneoplastic retinopathy. However, they have rarely been associated with neurological and psychiatric diseases with or without cancer. To date, there have been only a few identified cases of anti-recoverin antibody-associated limbic AE. CASE PRESENTATION: A 33-year-old North-African female with a family history of cancer and no relevant medical history presented to the neurology department of the Military Hospital of Tunis, Tunisia, with a 3-month history of temporal epilepsy, insomnia, and mild cognitive impairment. The episodes lasted 3-4 minutes. Scalp electroencephalogram showed bilateral epileptiform spikes and spike waves in the temporal regions. Brain magnetic resonance imaging showed bilateral hippocampal and thalamic hyperintense lesions on T2-weighted imaging with hypointensities in the same regions on T1-weighted imaging and no contrast enhancement. Anti-recoverin antibodies were strongly positive (3+) in blood and cerebrospinal fluid (CSF). The patient met the criteria for definite limbic AE after exclusion of alternative etiologies. The extended cancer work-up was unremarkable. The patient received 1 g daily of intravenous methylprednisolone for 5 days, along with 1000 mg/day of oral levetiracetam followed by 0.4 g/kg/day of intravenous immunoglobulin (IVIG) for 5 days. Levetiracetam was replaced by lamotrigine (100 mg/day) orally. During the 2-year follow-up, the patient's condition improved clinically and radiologically. Anti-recoverin antibody positivity persisted (1+) to date with minimal symptoms.
conclusionOur case illustrated the value of testing anti-recoverin antibodies in CSF and provides insights into management and prognosis through a longitudinal 2-year follow-up. Anti-recoverin antibody-related AE is a rare but treatable cause of adult subacute encephalopathy and epilepsy. Prompt and optimized management associating appropriate anti-epileptic drugs and immunotherapies is essential to alleviate sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.